...
首页> 外文期刊>Case Reports in Hematology >A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature
【24h】

A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature

机译:一例获得性VIII因子抑制剂并发与多种治疗有关的机会性感染并发文献复习

获取原文
           

摘要

This case report describes a patient with an idiopathic acquired Factor VIII inhibitor and severe bleeding. She was treated with rituximab after failing first-line treatment with steroids and cyclophosphamide. Two months following rituximab treatment, our patient developed a succession of severe opportunistic infections requiring intensive care unit admission. Over a period of 12 weeks she required treatment forPseudomonas aeruginosasepticaemia, herpes simplex gingivostomatitis and pharyngotonsillitis, clostridium difficile-related diarrhoea, systemic cytomegalovirus infection, pneumocystis jiroveci, and invasive pulmonary aspergillosis lung infections. After significant rehabilitation, the patient was finally discharged following a 5-month admission. This case highlights the complexity of balancing a life-threatening condition with the side effects of treatment. It also raises the issue of routine prophylaxis for immunosuppression in nonmalignant conditions, which will become a common dilemma with the expanding indications for rituximab use.
机译:该病例报告描述了患有特发性获得性凝血因子VIII抑制剂且出血严重的患者。一线类固醇和环磷酰胺治疗失败后,她接受了利妥昔单抗治疗。利妥昔单抗治疗后两个月,我们的患者发生了一系列严重的机会性感染,需要重症监护病房入院。在12周的时间内,她需要接受铜绿假单胞菌败血症,单纯疱疹性齿龈炎和咽喉炎,难辨梭状芽胞杆菌相关的腹泻,全身性巨细胞病毒感染,次生肺孢子虫和侵袭性肺曲霉病肺部感染的治疗。经过重大康复后,患者入院5个月后终于出院。这种情况突出了在危及生命的状况与治疗副作用之间取得平衡的复杂性。它还提出了在非恶性疾病中常规预防免疫抑制的问题,随着利妥昔单抗使用的适应症不断扩大,这将成为常见的难题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号